SCHEMBL30765732

SCHEMBL30765732

O=C(Cn1c(-c2ccccc2)ncc(NC(=O)c2noc(-c3ccccc3)n2)c1=O)NCc1cc2cnccc2[nH]1

nearest known ligand 0.40

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
NTRK1 P04629 2/20 0.40
CASP1 P29466 1/20 0.39
NTRK3 Q16288 1/20 0.38
DGAT2 Q96PD7 1/20 0.38
ELANE P08246 5/20 0.38
TSHR P16473 1/20 0.37
HDAC1 Q13547 3/20 0.37
HDAC6 Q9UBN7 2/20 0.37
HDAC8 Q9BY41 1/20 0.37
CMA1 P23946 1/20 0.36
CTRC Q99895 1/20 0.36
WNT3A P56704 1/20 0.36
SRPK1 Q96SB4 2/20 0.36
F3 P13726 1/20 0.36
DGAT1 O75907 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30766050 0.87 ELANE (0.41) NTRK1CASP1NTRK3ELANECMA1
SCHEMBL31558568 0.86 NTRK1 (0.45) NTRK1CASP1NTRK3ELANEHDAC1
SCHEMBL30766005 0.86 CASP1 (0.41) NTRK1CASP1NTRK3ELANEHDAC1
SCHEMBL30765851 0.84 NTRK1 (0.40) NTRK1CASP1NTRK3ELANEHDAC1
SCHEMBL30765443 0.83 ELANE (0.39) NTRK1CASP1NTRK3DGAT2ELANE
SCHEMBL30765697 0.83 F2 (0.43) NTRK1CASP1NTRK3ELANEHDAC6
SCHEMBL30765974 0.83 CASP1 (0.44) NTRK1CASP1NTRK3ELANEHDAC1
SCHEMBL30765478 0.83 CASP1 (0.41) NTRK1CASP1NTRK3ELANEHDAC1
SCHEMBL30765624 0.82 CASP1 (0.42) NTRK1CASP1NTRK3ELANEHDAC1
SCHEMBL30766049 0.82 NTRK1 (0.43) NTRK1CASP1NTRK3ELANECMA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4568666-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS Alexion Pharmaceuticals, Inc. (US) 2025-06-18 EP disclosed
CN-119768164-A Pharmaceutical compounds for treating complement-mediated disorders 阿雷克森制药公司 2025-04-04 CN disclosed
WO-2024035686-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2024-02-15 WO disclosed